

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

CSPC PHARMACEUTICAL GROUP LIMITED,
CSPC OUYI PHARMACEUTICAL CO., LTD., AND
CONJUPRO BIOTHERAPEUTICS, INC.,
Petitioners,

v.

IPSEN BIOPHARM LTD.,
Patent Owner.

Case No. IPR2025-00505
Patent No. 11,344,552

**JOINT STIPULATION TO MODIFY DUE DATES 2 AND 3
OF THE SCHEDULING ORDER**

On August 14, 2025, the Patent Trial and Appeal Board (PTAB) issued a Scheduling Order (Paper 14) in the above captioned *inter partes* review proceeding, setting forth due dates for the parties to take action in this trial. The Scheduling Order states that the parties may stipulate to different dates for the portion of DUE DATE 2 related to Petitioner's reply and the portion of DUE DATE 3 related to Patent Owner's sur-reply. (*Id.* at 9.)

As permitted by the PTAB in the Scheduling Order and in order to accommodate deposition scheduling, Patent Owner and Petitioners hereby stipulate to modify DUE DATES 2 and 3 as follows:

EVENT	DATE FROM SCHEDULING ORDER	DATE PURSUANT TO THIS STIPULATION
DUE DATE 2 (Petitioners' reply)	February 2, 2026	February 11, 2026
DUE DATE 3 (Patent Owner's sur-reply)	March 16, 2026	March 25, 2026

This stipulation does not affect or otherwise modify any other DUE DATES set in the Scheduling Order.

This paper is being filed on behalf of Petitioners with the approval of counsel for Patent Owner.

Respectfully submitted,

Dated: December 17, 2025

By: /s/ Lukas D. Toft
Lukas D. Toft (Reg. No. 75,311)
FOX ROTHSCHILD LLP
33 South 6th Street, Suite 3600
Minneapolis, MN 55402
Telephone: (612) 607-7336
Facsimile: (612) 607-7100
ltoft@foxrothschild.com

Joe Chen, Ph.D. (Reg. No. 70,066)
FOX ROTHSCHILD LLP
212 Carnegie Center, Suite 400
Princeton, NJ 08540
Telephone: (609) 844-3024
Facsimile: (609) 896-1469
joechen@foxrothschild.com

Howard S. Suh (*pro hac vice* pending)
Fox Rothschild LLP
101 Park Avenue, 17th Floor
New York, NY 10178
Telephone: (212) 878-7914
Facsimile: (212) 692-0940
hsuh@foxrothschild.com

**Attorneys for Petitioners CSPC
Pharmaceutical Group Limited, CSPC
Ouyi Pharmaceutical Co., Ltd., and
Conjurpro Biotherapeutics, Inc.**

CERTIFICATE OF SERVICE

Pursuant to 37 CFR § 42.6(e), the undersigned hereby certifies that on December 17, 2025, the foregoing Joint Stipulation to Modify Due Dates 2 and 3 was served via email on the following counsel of record for Patent Owner:

Lead Counsel

James M. Glass, Reg. No. 46,729
jimglass@quinnemanuel.com
michaellabas@quinnemanuel.com

Backup Counsel

Angus Chen, Reg. No. 73,566
anguschen@quinnemanuel.com

Quincy Lu, Reg. No. 76,954
quincylu@quinnemanuel.com

Catherine Mattes, Reg. No. 68,346
catherinemattes@quinnemanuel.com

Elizabeth Murphy (*pro hac vice* forthcoming)
elizabethmurphy@quinnemanuel.com

Ross Misskelley (*pro hac vice* forthcoming)
rossmisskelley@quinnemanuel.com

Dated: December 17, 2025

/s/ Lukas D. Toft

Lukas D. Toft (Reg. No. 75,311)
Counsel for Petitioners